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To determine the susceptibility of AMPLICOR Chlamydia trachomatis PCR to inhibitory factors possibly
present in cervical specimens, we obtained cervical specimens from 200 gynecology patients attending our
outpatient clinic. The prevalence of C. trachomatis infection was 4.1%, as determined by cell culture. All
AMPLICOR specimens were tested in one procedure as described by the manufacturer, and after the specimen
was spiked with C. trachomatis, several other pretreatment protocols were used. Complete inhibition of the PCR
was observed in 38 (19%) cervical specimens. Heat treatment at 95&C, freeze-thawing, or 10-fold dilution of the
samples reduced the initial inhibition to 9, 16, or 9%, respectively. A combination of heat treatment and 10-fold
dilution reduced the inhibition to 4% of the samples. A second specimen type (swabs inoculated in 0.2 M
sucrose phosphate buffer [2SP]) was also evaluated. A 10-fold dilution of the spiked 2SP specimens resulted
in an inhibition rate of 6%, which was comparable to that obtained by centrifugation of the 2SP specimen prior
to processing. Furthermore, it was shown that the inhibition was not correlated with blood contamination.
Processing the specimens on the day of collection or the day after resulted in a higher inhibition rate than did
delayed processing (27.6 versus 15.5%, respectively). An inverse correlation was found between the concentra-
tion of C. trachomatis added to the sample and the rate of inhibition observed. The inhibition was partly
correlated with the pH of the cervical mucosa. Decreased inhibition was found at pH values of>7.5. The effects
of blood, pH, and delay in processing were all evaluated by using the AMPLICOR specimen. We conclude that
the susceptibility of AMPLICOR C. trachomatis PCR to inhibiting factors in cervical specimens can be
significantly reduced if the pretreatment procedure includes heat treatment or the use of 2SP transport
medium. Also, a 10-fold dilution of the clinical specimen followed by heat treatment will largely prevent the
inhibition of this PCR.
In most studies, the sensitivity of AMPLICOR PCR for the
detection of Chlamydia trachomatis in cervical specimens has
been at least comparable to that of cell culture (1, 3, 7, 9).
Nevertheless, several investigators have detected false-nega-
tive PCR results and suggested that certain inhibiting factors
present in the cervical specimen may compromise the sensitiv-
ity of the assay. These shortcomings of the assay should be
overcome by optimization of the sample pretreatment proce-
dure in order to neutralize inhibitors in the specimen (1, 2, 5,
7).
In the present study, we evaluated the susceptibility of the
Roche AMPLICOR C. trachomatis PCR assay to inhibitory
factors possibly present in cervical specimens by spiking sam-
ples with a known number of elementary bodies. Furthermore,
to circumvent false-negative results due to inhibition, several
sample pretreatment protocols were studied.
(This work was presented in part at the 35th Interscience
Conference on Antimicrobial Agents and Chemotherapy, San
Francisco, Calif., 17 to 20 September 1995, and at the First
European Meeting on Diagnostic PCR, Amsterdam, The
Netherlands, 12 to 13 October 1995.)
MATERIALS AND METHODS
Patients and specimens. Cervical specimens were collected from 200 women
visiting the outpatient clinic for gynecology at the University Hospital in Rot-
terdam, The Netherlands. Two cervical specimens per patient were obtained:
one AMPLICOR specimen and one cell culture specimen. The AMPLICOR
specimen was collected by using the STD swab specimen collection and transport
kit (Roche Diagnostic Systems, Branchburg, N.J.). The specimen was taken
according to the manufacturer’s guidelines. The specimen used for cell culture
was collected with a Dacron swab (Medical Wire and Equipment Co., Corsham,
Wiltshire, United Kingdom) and placed into 0.2 M sucrose phosphate buffer
(2SP). The specimens were stored at room temperature and sent to the labora-
tory within 4 h. The AMPLICOR sample was stored at 48C prior to processing.
The 2SP sample for cell culture was stored at 48C, or at 2708C when not
processed within 24 h after collection. Blood contamination of the AMPLICOR
specimen was registered. The cervical pH was tested in situ with colorfast pH
indicator sticks (Merck, Darmstadt, Germany).
AMPLICOR PCR. A protocol was developed to analyze PCR inhibition in
cervical samples in a controlled manner. Cervical specimens were deliberately
spiked with C. trachomatis serovar D prior to the PCR. The stock solution was
stored at 2808C in small aliquots prior to use. The stock contained 1.5 3 104
inclusion-forming units (IFU) of C. trachomatis per ml. Aliquots of the AMPLI-
COR specimens were spiked with a concentration of 100 IFU per PCR and
processed by one of the following procedures: (i) that prescribed by the manu-
facturer’s guidelines, (ii) heat treatment at 958C for 10 min prior to the PCR, (iii)
freeze-thawing twice in liquid nitrogen prior to the PCR, (iv) pretreating the
sample at 48C, (v) a 10-fold dilution with AMPLICOR transport buffer prior to
the PCR, or (vi) a 10-fold dilution in AMPLICOR transport buffer and subse-
quent heating of the sample at 958C for 10 min prior to the PCR. Furthermore,
the 2SP specimens were also spiked with a concentration of 100 IFU per reaction
and processed by one of the following procedures: (i) specimens were diluted
10-fold with AMPLICOR transport buffer and processed as prescribed by the
manufacturer, or (ii) 100 ml of 2SP specimen was centrifuged at 10,000 3 g for
5 min at room temperature, resuspended in 100 ml of AMPLICOR transport
buffer, and processed by a scaled-down version of the manufacturer’s method for
processing AMPLICOR swab specimens. Statistical evaluation of the collected
data was performed by Fisher’s exact test. Statistical significance was accepted at
P # 0.05 (two-tailed).
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RESULTS
Inhibition was observed in 38 (19.0%) of the cervical spec-
imens when the AMPLICOR protocol was used as prescribed
by Roche (protocol i). Heat treatment to 958C for 10 min prior
to processing (protocol ii) reduced the initial inhibition rate
significantly to 9.3% (P 5 0.032). Only one sample initially
positive by PCR became negative with this pretreatment pro-
cedure. Freeze-thawing (protocol iii) resulted in no significant
decrease in the initial rate of inhibition. (The inhibition rate
was 15.7% [P 5 0.535].) Three initially positive samples be-
came negative with this particular treatment procedure. Also,
adding cold specimen diluent to specimens and incubating
them for 10 min at 48C, instead of room temperature, did not
change the inhibition rate significantly. (The inhibition rate
was 21.2% [P 5 0.655].) In contrast, a 10-fold dilution of the
sample resulted in an inhibition rate of 9.3%, while a combi-
nation of heat treatment with a 10-fold dilution resulted in an
inhibition rate of only 4.1% (P 5 0.041 and 0.0003, respec-
tively, compared with the initial inhibition rate found with the
procedure prescribed by Roche) (Table 1). Eight initially in-
hibited samples became positive after this combined proce-
dure, while none of the initially positive samples became neg-
ative.
The patient samples transported in 2SP were also spiked
with C. trachomatis elementary bodies at a concentration of
100 IFU per PCR and tested by two different pretreatment
methods. A 10-fold dilution of the 2SP specimen resulted in a
low inhibition rate of 5.8%, which was comparable to the rate
obtained by centrifugation of the 2SP specimen prior to pro-
cessing of the sample (P 5 0.0002, compared with the initial
inhibition rate) (Table 1).
To gain insight into the nature of the inhibitory factor(s), 34
AMPLICOR specimens were spiked with either 10, 50, or 250
IFU of C. trachomatis per PCR before the PCR was carried out
as prescribed by the manufacturer. It can be observed that the
number of negative samples decreased as the number of target
DNA molecules increased (Fig. 1). The inhibition rates were
23.5, 17.6, and 14.7%, respectively, with the procedure pre-
scribed by Roche Molecular Systems. This dose-dependent
effect was circumvented by 10-fold dilution of the specimens,
which resulted in inhibition rates of 8.8, 5.9, and 11.8%, re-
spectively.
Another factor which was taken into account was the stabil-
ity of the inhibitory factor(s). One hundred sixty-eight speci-
mens (84%) were processed within 7 days. Processing the spec-
imens on the day of collection or the day after resulted in a
higher inhibition rate than was obtained by delayed processing.
The inhibition rates found were 27.6 and 15.5%, respectively
(P 5 0.072).
Since it is known that blood can be inhibitory to PCR, the
blood-containing specimens were evaluated vis-a`-vis the spec-
imens without visible blood contamination. Thirty-two of 163
specimens (19.6%) without visible blood contamination were
inhibited by PCR. Thirty-seven specimens were contaminated
with blood; of these, 6 (16.2%) were inhibited, a rate not
significantly different from that found in specimens without
blood contamination.
Furthermore, the pHs of the cervical mucosae were regis-
tered for 126 patients to study if there is a correlation between
the pH and the rate of inhibition. No significant correlation
was found between the pHs of the cervical mucosae and the
inhibition rate. Of 42 specimens taken from women with cer-
vical pHs between 3.5 and 5.5, 9 (21.4%) were inhibitory for
PCR. Of 69 specimens from women with cervical pHs between
5.5 and 7.5, 14 (20.3%) showed inhibition. Fifteen patients had
cervical pHs of $7.5; for this group, the inhibition rate ob-
served was reduced, but not significantly different, from that
for the patient group with cervical pHs of,7.5 (6.7 and 20.7%,
respectively; P 5 0.30).
DISCUSSION
Failure to detect C. trachomatis-specific DNA by PCR in
cervical specimens has been reported by others (1, 2, 4–8,
10–12). Some inhibitors could be removed by dilution or heat
treatment of the sample prior to processing for PCR (4, 6, 8,
12). Also, prolonged storage of the AMPLICOR specimen
reduced the inhibitory activity in several studies (2, 7, 10). The
use of alternative transport procedures can increase the sensi-
tivity of the PCR. 2SP has been reported to be an improved
transport medium for AMPLICOR PCR (11). Also, freezing
the sample in saline or resuspending a dried endocervical swab
in saline has been reported to increase the sensitivity of AM-
PLICOR PCR (1, 5).
The aim of the present study was to determine the impact of
possible PCR inhibitors in cervical specimens with the AM-
PLICOR C. trachomatis assay, with a view to further improve-
TABLE 1. Effect of additional pretreatment procedure and
transport medium on the inhibition of AMPLICOR C. trachomatis
PCR assay
Specimen and additional pretreatment method % of samplesinhibited P
a
AMPLICOR
None 19.0
Heating 10 min at 958C 9.3 0.032
Freeze-thawing twice 15.7 0.535
10-fold dilution 9.3 0.041
10-fold dilution followed by heating 10 min
at 958C
4.1 0.0003
Pretreatment at 48C 21.2 0.655
2SP
10-fold dilution 5.8 0.0002
Centrifugation 5.8 0.0002
a Compared with AMPLICOR pretreatment protocol prescribed by the man-
ufacturer’s guidelines; measured by Fisher’s exact test.
FIG. 1. Effect of target DNA concentration on the inhibition of AMPLICOR
C. trachomatis PCR assay (n 5 34).
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ment of the diagnosis of C. trachomatis infections by PCR.
Significant inhibition was observed frequently in cervical spec-
imens when the AMPLICOR protocol prescribed by Roche
Diagnostic Systems was used. The inhibition was clearly in-
versely correlated with the target DNA concentration. This
phenomenon was not observed if a 10-fold dilution of the
sample was used, indicating a baseline inhibition which will
remain present despite an increase in target DNA load.
The inhibitory activity found in our study can be reduced by
delayed testing, which would indicate the presence of instable
compounds, such as hormones and/or enzymes, that become
inactive over time. This phenomenon has been confirmed by
several other investigators (2, 7, 10). Also, the pH of the cer-
vical mucosa may be partially responsible for the inhibition.
Decreased inhibition was found at pH values of $7.5. A 10-
fold dilution of the AMPLICOR specimen will increase the pH
and therefore reduce the effect of pH. It can be concluded that
PCR inhibitory activity in cervical specimens can be largely
removed by heat treatment, a 10-fold dilution, or a combina-
tion of the two. Also, the use of 2SP as an alternative transport
medium for the AMPLICOR C. trachomatis PCR assay has a
similar effect. This can be explained by the pretreatment pro-
cedure. Using only the sediment after centrifugation or a 10-
fold diluted sample will diminish the effect of all soluble in-
hibitory compounds.
Freeze-thawing twice prior to processing had only a minor
effect on the outcome of the PCR. However, three initially
positive specimens became negative. This could indicate that
freeze-thawing destroys target DNA, resulting in decreased
sensitivity of the PCR assay. DNase may also be responsible for
this phenomenon.
In response to the results found in this study, it would be
preferable to routinely include an internal control in each
amplification mixture, which would greatly improve the quality
of diagnosis of C. trachomatis infections.
The impact of these newly defined pretreatment methods
can be observed only in a clinical study to determine the prev-
alence of inhibitory factors in C. trachomatis-positive patients.
The specimens would have to be tested in a prospective man-
ner to overcome major differences between the study and rou-
tine clinical practice. Batch processing of the specimens after
storage can reduce the inhibitory effect, as was demonstrated
in the present study. Many patients would have to be included
to accomplish such a study. Since this is very labor-intensive,
we decided to perform the present prospective controlled
study.
We have studied the prevalence of C. trachomatis in patients
attending the outpatient clinic for gynecology in a general
hospital, Diakonessen, Utrecht, The Netherlands by using 2SP
as an alternative transport medium for AMPLICOR PCR, and
we have compared these results with those of cell culture. In
this study, the sensitivities of AMPLICOR PCR and cell cul-
ture were 97 and 69%, respectively (data not published). In
another ongoing study, we evaluated the COBAS AMPLICOR
PCR for the detection of C. trachomatis and Neisseria gonor-
rhoeae in urine and compared the results with those of cell
culture. An internal control was incorporated in this evalua-
tion. At the time the data reported in this article were tabu-
lated, 1,000 patients were enrolled in this study. Twenty-six
patients had results indicating inhibition of the PCR. Only one
specimen remained inhibited after being heated at 958C for 10
min. Two patients became positive for N. gonorrhoeae after
successful PCR processing. No inhibition was found when a
10-fold dilution was used, although the two positive N. gonor-
rhoeae specimens became negative after dilution, indicating a
reduction in sensitivity.
We conclude that AMPLICOR C. trachomatis PCR for cer-
vical specimens can be significantly improved if the pretreat-
ment procedure includes heat treatment or the use of 2SP
transport medium. A 10-fold dilution of the clinical specimen
followed by heat treatment will also decrease PCR inhibition
significantly.
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